DERM Secures Russell 2000/3000 Placement, Boosting Visibility

Rhea-AI Filing Summary

Journey Medical Corporation (NASDAQ: DERM) filed an 8-K reporting its forthcoming inclusion in the Russell 2000 and Russell 3000 indices, effective after the U.S. market close on June 27 2025. The change follows FTSE Russell’s annual reconstitution and does not involve any new financial results or transactions. Index inclusion typically increases stock visibility and can lead to incremental demand from passive funds benchmarked to the Russell family. The company attached the related press release as Exhibit 99.1; no other operational or financial updates were disclosed.

Positive

• Russell 2000/3000 inclusion enhances stock visibility and may attract passive fund inflows, improving liquidity and potential valuation.

Negative

• None.

Insights

Equity Index Analyst

Journey Medical's addition to Russell 2000/3000 indices brings institutional visibility and potential increased trading volume.

Journey Medical's inclusion in the Russell 2000® and Russell 3000® indices represents a significant milestone for the dermatology-focused pharmaceutical company. This development, effective June 27, 2025, places DERM among the recognized small-cap benchmarks tracked by institutional investors nationwide.

The Russell indices reconstitution is a methodical, market-cap based process that occurs annually. The Russell 2000® specifically captures the small-cap segment of the US equity market, while the Russell 3000® encompasses approximately 98% of the investable domestic equity universe.

This inclusion typically triggers mechanical buying from index funds and ETFs that track these benchmarks, as they must add Journey Medical shares to maintain accurate index replication. Beyond this technical aspect, inclusion generally enhances trading liquidity and institutional visibility.

For emerging growth companies like Journey Medical, Russell index membership represents external validation of the company's market position and growth to date. The inclusion doesn't alter Journey Medical's fundamental operations or financial outlook, but it does place the company within a widely-recognized investment framework that serves as a performance benchmark for professional money managers.

false 0001867066 0001867066 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2025

Journey Medical Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware		001-41063		47-1879539
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

9237 E Via de Ventura Blvd., Suite 105

Scottsdale, AZ 8525

(Address of principal executive offices)

Registrant’s telephone number, including area code: (480) 434-6670

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	DERM	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On June 24, 2025, Journey Medical Corporation (“Journey Medical” or the “Company”) announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025. A copy of the press release issued by Journey Medical is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished herewith:

Exhibit Number		Description
99.1		Press release issued by Journey Medical Corporation, dated June 24, 2025
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Journey Medical Corporation
	(Registrant)
	By:	/s/ Claude Maraoui
		Claude Maraoui
		Chief Executive Officer, President and Director

Date: June 24, 2025

FAQ

When will Journey Medical (DERM) join the Russell 2000 and Russell 3000 indices?

After the market closes on June 27 2025.

Does the 8-K include any new financial results for Journey Medical?

No. The filing only reports index inclusion; no earnings or balance-sheet data were provided.

Why is joining the Russell 2000 important for DERM investors?

Index addition can boost trading liquidity, attract passive fund buying, and raise the company’s market visibility.

Which exhibit contains the official press release about the index inclusion?

Exhibit 99.1 holds the press release dated June 24 2025.

Will the index change affect Journey Medical’s business operations?

No direct operational impact. The change is market-related and does not modify the company’s strategy or products.